These data were consistent with a previous finding that SMYD3 could activate MAP kinase signaling through methylating MAP3K2 and promote the formation of Ras-driven carcinomas [59] and remodel the tumor microenvironment by activation of MEK/ERK [60]. This evidence concerns the gene MAPK1 and carcinoma.